Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen

International Journal of Cancer

Volumn 101, Issue 3, 2002, Pages 280-286

  Labarrière, Nathalie ^a   Bretaudeau, Laurent ^a,b   Gervois, Nadine ^a,c   Bodinier, Marie ^a   Bougras, Gwenola ^a   Diez, Elisabeth ^a   Lang, François ^a   Gregoire, Marc ^a   Jotereau, Francine ^a,c  

^a INSERM   (France)

^b IDM (Immune Designed Molecules)   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Antigen presentation; Apoptosis; Cross priming; Cytotoxic T lymphocyte; Dendritic cell

Indexed keywords

ANTIGEN; HLA A ANTIGEN; MELAN A; NA17 A ANTIGEN; PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; CELL SELECTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; MELANOMA CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; APOPTOSIS; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; IMMUNOMAGNETIC SEPARATION; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PHAGOCYTOSIS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0037144351     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10605     Document Type: Article

References (33)

1. Dendritic cells and the control of immunity
2. Immunobiology of dendritic cells
3. The makings of a tumor rejection antigen
4. The dendritic cell system and its role in immunogenicity
5. + melanoma patients by mature monocyte-derived dendritic cells
6. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
7. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
8. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
9. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
10. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells
11. Processing of engulfed apoptotic bodies yields T cell epitopes
12. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
13. Induction of antigen presentation by macrophages after phagocytosis of tumour apoptotic cells
14. + T cells for efficient tumor cell lysis
15. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response
16. Dead or alive: Immunogenicity of human melanoma cells when presented by dendritic cells
17. Dendritic cells as vectors for therapy
18. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
19. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene
20. + cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: Cytotoxic activity and T cell receptor gene rearrangements
21. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding
22. Phenotypic analysis of antigen-specific T lymphocytes
23. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry
24. Monocyte-derived dendritic cells: Development of a cellular processor for clinical applications
25. Standardized generation of fully mature p70 IL-12 monocyte-derived dendritic cells for clinical use
26. High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells
27. Detection of intracellular cytokines by flow cytometry
28. High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy
29. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription
30. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
31. Natural adjuvants: Endogenous activators of dendritic cells
32. A role for CD36 in the regulation of dendritic cell function
33. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells